Topics

Novo Nordisk, Bluebird partner for gene-editing deal for hemophilia A

05:40 EDT 10 Oct 2019 | SmartBrief

A three-year collaborative deal between Novo Nordisk and Bluebird Bio will initially focus on developing one-time treatments  -More

Original Article: Novo Nordisk, Bluebird partner for gene-editing deal for hemophilia A

NEXT ARTICLE

More From BioPortfolio on "Novo Nordisk, Bluebird partner for gene-editing deal for hemophilia A"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...